Journal article
Comparison of cholesterol-lowering regimens
American family physician, v 42(3), pp 761-768
Sep 1990
PMID: 2168121
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Drug therapy should be reserved for patients with marked total cholesterol elevation not amenable to dietary measures. While current guidelines suggest that bile acid sequestrants, such as cholestyramine and colestipol, are first-line drugs for the treatment of hypercholesterolemia, recent studies suggest that lovastatin is a safe, more potent alternative. Gemfibrozil reduces the serum triglyceride level and raises the high-density lipoprotein (HDL) cholesterol level, but has only a moderate effect on the serum cholesterol level. Nicotinic acid lowers serum low-density lipoprotein (LDL) cholesterol and triglyceride levels and raises serum HDL levels, but its use is limited because of troublesome side effects, notably a flushing reaction. Probucol lowers both serum LDL and HDL levels and is a second-line agent for the treatment of hypercholesterolemia.
Metrics
14 Record Views
Details
- Title
- Comparison of cholesterol-lowering regimens
- Creators
- S Snyder - Hahnemann University School of Medicine, Philadelphia, Pennsylvania
- Publication Details
- American family physician, v 42(3), pp 761-768
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Civil, Architectural, and Environmental Engineering
- Web of Science ID
- WOS:A1990DX22100024
- Scopus ID
- 2-s2.0-0025148111
- Other Identifier
- 991019184178604721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Primary Health Care